MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.